Home›Stock Screener›Kabra Drugs

Kabra Drugs Share Price Today | Stock Price & Kabra Drugs Share Screener

KABRADG Pharmaceuticals & Biotechnology
Live Share Price BSE
₹19.00
▲ 0.37 (1.99%)
2026-11-18 00:00:00

As of November 18, 2026, the live Kabra Drugs share price (BSE: KABRADG) is ₹19.00, up 1.99% from the previous close, with shares trading between ₹18.00 and ₹19.80 in today's trading session, and a 52-week range of ₹15.70–₹34.67. Track Kabra Drugs marketcap in USD to gauge the company's total market size. Use the Kabra Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Kabra Drugs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹144 and net income of ₹8, with EBITDA of ₹10, an operating margin of 7.0% and a profit margin of 5.6%.

Kabra Drugs Market Cap ₹48.59 Cr.
KABRADG P/E Ratio (TTM) 6.30
Kabra Drugs P/B Ratio 1.44
EPS (TTM) ₹2.09
Dividend Yield -
Debt to Equity 0.02
KABRADG 52 Week High ₹34.67
Kabra Drugs 52 Week Low ₹15.70
Operating Margin 7.00%
Profit Margin 5.56%
KABRADG Revenue (TTM) ₹144.00
EBITDA ₹10.00
Net Income ₹8.00
Total Assets ₹86.00
Total Equity ₹30.00

Kabra Drugs Share Price Chart

Track the current stock price of Kabra Drugs with an interactive chart. Analyse KABRADG share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Kabra Drugs stock quote in one place.

The quote of ₹19.00 sits between the 52-week low of ₹15.70 and the 52-week high of ₹34.67, and the latest session moved 1.99% from the previous close.

Kabra Drugs Company Profile - Fundamental Screener

Screen Kabra Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for KABRADG shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE323K01017.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE323K01017

Kabra Drugs Balance Sheet Screener

Screen KABRADG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹86, up from ₹25 in 2025.

Latest statistics put total assets at ₹86 and shareholder funds at ₹30, with a leverage ratio of 0.02.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 86 25 5 1 1 1 1 2 2 6
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 1 0 0 0 0 0 0 0 0 3

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 0 0 0 0 0 0 1
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 30 25 1 -1 0 0 0 0 0 3
Share Capital 24 24 4 4 4 4 4 4 4 4
Reserves & Surplus 6 1 -6 -5 -5 -5 -4 -4 -4 -2

Kabra Drugs Income Statement Screener - Profit & Revenue Analysis

Screen Kabra Drugs income statement and profit fundamentals. Analyze KABRADG quarterly results. Kabra Drugs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹144 and net profit was ₹8, equal to earnings per unit of ₹3.20, at an operating margin of 7%.

In that period expenses were ₹135, interest cost ₹0 and tax ₹2. The next period listed, 2026-March, shows revenue of ₹93 and net profit of ₹5.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 144 93 1 0 0 0 0 0 0 2 8 10 8
Expenses 135 87 2 1 0 0 0 0 0 3 7 9 8

Operating Costs and Margins

EBITDA 10 6 -1 -1 0 0 0 0 0 -1 1 1 0
Operating Profit % 7.00% 6.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.00% 6.00% 5.00% 5.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 9 6 -1 -1 0 0 0 0 0 -2 0 0 0
Tax 2 1 0 0 0 0 0 0 0 0 0 0 0
Net Profit 8 5 -1 -1 0 0 0 0 0 -2 0 0 0
EPS 3.20 2.09 -0.99 -1.68 -0.77 -0.42 -0.41 -0.14 -0.38 -5.37 0.30 0.06 0.16

Kabra Drugs Cash Flow Screener - Liquidity Fundamentals

Screen KABRADG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹10, and net cash flow was an outflow of ₹11.

Over the same period, investing activities used ₹1 and financing activities provided ₹0.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities -10 -5 0 0 0 0 0 0 0 0
Investing Activities -1 0 0 0 0 0 0 0 2 0

Financing and Net Cash

Financing Activities 0 23 3 0 0 0 0 0 -1 0
Net Cash Flow -11 19 3 0 0 0 0 0 0 0

Kabra Drugs Shareholding Pattern Screener

See Kabra Drugs shareholding pattern with promoter, FII, and DII holdings. Check Kabra Drugs promoter holding and ownership changes for KABRADG on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 0.00%, foreign institutions 0.00%, domestic institutions 0.00% and the public 90.92%, spread across 9,185 shareholders.

The shareholder count was 9,185 in 2026-Mar, compared with 9,680 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 90.92% 90.69% 90.88% 95.94% 95.61% 95.00% 91.43% 95.73%
Other Holding 9.08% 9.31% 9.12% 4.06% 4.39% 5.00% 8.57% 4.27%
Shareholder Count 9,185 9,680 9,727 7,435 7,449 8,098 8,862 7,364

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Kabra Drugs. Kabra Drugs dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Kabra Drugs.

Kabra Drugs Stock Index Membership - Nifty & Sensex

See which indices include Kabra Drugs stock. Check KABRADG index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Kabra Drugs is not part of any tracked indices.
Only major market indices are tracked in our system.

Kabra Drugs Market Events Screener - Corporate Actions

Get Kabra Drugs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Kabra Drugs stock events that may affect KABRADG share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 6, 2026, with a record date of November 6, 2026.

It is followed by Annual General Meeting dated September 30, 2026 and Quarterly Result Announcement dated August 12, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-06 2026-11-06 Quarterly Result Announcement NA 1.34%
2026-09-30 2026-09-30 Annual General Meeting NA 5.24%
2026-08-12 2026-08-12 Quarterly Result Announcement NA -1.50%
2026-05-29 2026-05-29 Quarterly Result Announcement NA 0.36%
2026-02-13 2026-02-13 Quarterly Result Announcement NA 11.26%
2025-12-26 2025-12-26 Extraordinary General Meeting NA -0.91%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 7.48%
2025-09-30 2025-09-30 Annual General Meeting NA -1.53%
2025-08-14 2025-08-14 Quarterly Result Announcement NA 1.97%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 0.00%
2025-02-14 2025-02-14 Quarterly Result Announcement NA 4.97%
2025-01-02 2025-01-02 Extraordinary General Meeting NA 4.90%
2024-11-14 2024-11-14 Quarterly Result Announcement NA 4.92%
2024-09-30 2024-09-30 Annual General Meeting NA 4.94%
2024-02-17 2024-02-17 Extraordinary General Meeting NA 10.13%

Kabra Drugs Competitors Screener - Peer Stocks Comparison

Screen KABRADG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

Kabra Drugs Company Announcements - News & Reports Screener

Screen KABRADG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 10, 2026.

The next most recent announcements are dated November 10, 2026 and November 10, 2026.

Date Update Actions
2026-11-10 Undertaking For Non- Applicability Of Regulation 32 Of SEBI (LODR) Regulations 2015 For The Quarter Ended On 30Th September 2026 -
2026-11-10 Financial Results For The Quarter Ended 30-September-2026 -
2026-11-10 Board Meeting Outcome for Outcome Of Board Meeting Held On 06-November-2026 As Per Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-30 Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 06Th November 2026 -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-28 Closure of Trading Window -
2026-09-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-08 Reg. 34 (1) Annual Report. -
2026-09-07 Submission Of Notice Of Annual General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations 2015 -
2026-09-03 Book Closure And Schedule Of Events For E-Voting. -
2026-09-02 Appointment Of Internal Auditor Of The Company -
2026-09-02 Appointment Of Secretarial Auditor Of The Company -
2026-09-02 Board Meeting Outcome for Outcome Of Board Meeting Held On 02Nd September 2026 -
2026-08-29 Announcement under Regulation 30 (LODR)-Change in Registered Office Address -
2026-08-27 Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 02Nd September 2026 -
2026-08-18 Reconstitution Of The Composition Of The Board & Committees Of Regulation 30 Of SEBI (LODR) Regulations 2015 -
2026-08-18 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-12 Announcement under Regulation 30 (LODR)-Resignation of Director -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹19.00, within a 52-week range of ₹15.70 to ₹34.67. The P/E ratio is 6.30 and the P/B ratio is 1.44, with earnings per unit of ₹2.09. Market capitalisation stands at ₹48.59 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.